Key Points
- Donald Notman, Ocular Therapeutix’s COO, sold a total of 11,490 shares in two filings (5,455 on Feb 2 at $9.14 and 6,035 on Feb 4 at $8.54), generating about $101,398 and reducing his stake (he held 383,837 shares after the Feb 2 sale).
- Company results and analyst view: Ocular reported Q EPS of ($0.29) which beat estimates, with revenue of $13.25M down 22.4% year-over-year and continued negative margins/ROE; analysts maintain a "Moderate Buy" consensus with an average price target of $22.56.
Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) COO Donald Notman sold 5,455 shares of the firm's stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $9.14, for a total transaction of $49,858.70. Following the completion of the transaction, the chief operating officer directly owned 383,837 shares in the company, valued at $3,508,270.18. This represents a 1.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.
Donald Notman also recently made the following trade(s):
- On Wednesday, February 4th, Donald Notman sold 6,035 shares of Ocular Therapeutix stock. The shares were sold at an average price of $8.54, for a total value of $51,538.90.
Ocular Therapeutix Stock Performance
Shares of NASDAQ:OCUL opened at $8.55 on Thursday. The company has a debt-to-equity ratio of 0.27, a current ratio of 7.85 and a quick ratio of 7.78. Ocular Therapeutix, Inc. has a 1 year low of $5.78 and a 1 year high of $16.44. The firm has a market capitalization of $1.82 billion, a PE ratio of -5.94 and a beta of 0.90. The business's 50 day moving average price is $11.94 and its 200-day moving average price is $11.97.
Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last announced its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, beating analysts' consensus estimates of ($0.34) by $0.05. Ocular Therapeutix had a negative return on equity of 86.33% and a negative net margin of 447.57%.The company had revenue of $13.25 million for the quarter. During the same quarter in the previous year, the business posted ($0.29) EPS. The company's revenue for the quarter was down 22.4% on a year-over-year basis. As a group, equities research analysts expect that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of research analysts have weighed in on OCUL shares. Needham & Company LLC reissued a "buy" rating and issued a $20.00 target price on shares of Ocular Therapeutix in a research note on Monday, December 8th. Weiss Ratings reissued a "sell (d-)" rating on shares of Ocular Therapeutix in a research note on Thursday, January 22nd. Royal Bank Of Canada restated an "outperform" rating on shares of Ocular Therapeutix in a report on Wednesday, November 5th. HC Wainwright lifted their price target on Ocular Therapeutix from $19.00 to $21.00 and gave the stock a "buy" rating in a report on Monday, December 8th. Finally, TD Cowen reissued a "buy" rating on shares of Ocular Therapeutix in a report on Thursday, October 30th. Eleven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $22.56.
Read Our Latest Stock Report on Ocular Therapeutix
Institutional Trading of Ocular Therapeutix
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. lifted its stake in Ocular Therapeutix by 17.0% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,154 shares of the biopharmaceutical company's stock worth $57,000 after purchasing an additional 893 shares in the last quarter. The Manufacturers Life Insurance Company lifted its stake in Ocular Therapeutix by 1.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 72,618 shares of the biopharmaceutical company's stock worth $674,000 after acquiring an additional 1,314 shares in the last quarter. Nisa Investment Advisors LLC lifted its stake in Ocular Therapeutix by 62.9% during the 2nd quarter. Nisa Investment Advisors LLC now owns 3,604 shares of the biopharmaceutical company's stock worth $33,000 after acquiring an additional 1,392 shares in the last quarter. Trust Co. of Vermont boosted its holdings in Ocular Therapeutix by 24.3% during the 4th quarter. Trust Co. of Vermont now owns 8,950 shares of the biopharmaceutical company's stock valued at $109,000 after acquiring an additional 1,750 shares during the period. Finally, Profund Advisors LLC grew its position in Ocular Therapeutix by 9.9% in the 3rd quarter. Profund Advisors LLC now owns 25,178 shares of the biopharmaceutical company's stock valued at $294,000 after acquiring an additional 2,272 shares in the last quarter. Hedge funds and other institutional investors own 59.21% of the company's stock.
Ocular Therapeutix Company Profile
(
Get Free Report)
Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.
The company's flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
